Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if BMS-247550 added to the approved
therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth
of the cancer in women with metastatic breast cancer who are resistant to taxane and received
anthracycline chemotherapy. The safety of this treatment will also be studied.